This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® Serotypes matterBurden of diseaseIPDCAPPatient profilesPatient
profilesAge 50+: Arlene, Age 51Diabetes: David, Age 46Asthma: Carly, Age 30COPD: William, Age 48Age 65+: Tyrell, Age 67 Risk for All Underlying Medical ConditionsMary, 65: Healthy ≥65; Unknown Vaccination HistoryCDC recommendationsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyAdministrationAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideosEvents
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
CDC recommendations:
All eligible adults aged 50+ are recommended for pneumococcal vaccination1-3​​
The CDC recommends Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) for ALL of the following eligible adult patients 1-3:

See ACIP recommendations for the full set of pneumococcal adult recommendations.

You can help protect ALL your eligible adult patients aged 50+ and aged 19 to 49 with certain underlying medical conditions.1-3​
View eligible patient types
Loading ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CSF=cerebrospinal fluid; HIV=human immunodeficiency virus; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.
*Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.3
†If PCV13 was administered at any age and PPSV23 was administered before age 65 years with the last pneumococcal vaccine being at least 5 years prior, then the patient is eligible for Prevnar 20 as part of a routine vaccination. Based on shared clinical decision-making, a patient is eligible to receive Prevnar 20 if PCV13 (but not PCV15, PCV20, or PCV21) was administered at any age, PPSV23 was administered at or after the age of 65, and the last pneumococcal vaccine was at least 5 years prior.3
‡Adults with chronic medical conditions were previously not recommended to receive PCV13, and there is no current CDC recommendation for those who have received both PCV13 and PPSV23.3
§Also applies to those with an immunocompromising condition (listed below) who have received PCV13 plus 2 doses of PPSV23.3

Underlying medical conditions or other risk factors:

Alcoholism; chronic heart disease (including CHF and cardiomyopathies); chronic liver disease; chronic lung disease (including COPD, emphysema, and asthma); chronic renal failure||; cigarette smoking; cochlear implant; congenital or acquired asplenia||; cerebrospinal fluid leak; diabetes; generalized malignancy||; HIV infection||; Hodgkin disease||; congenital or acquired immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders [excluding chronic granulomatous disease])||; iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)||; leukemia||; lymphoma||; multiple myeloma||; nephrotic syndrome||; solid organ transplant||; sickle cell disease or other hemoglobinopathies||.3
||Immunocompromising conditions.3
References:Prevnar 20 ® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.  Kobayashi M. Summary of Work Group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. Presented at: Advisory Committee on Immunization Practices; October 23, 2024; Atlanta, GA. Accessed October 23, 2024. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pneumococcal-508.pdf  Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 2024. Accessed November 13, 2024. https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf
See resources and coverage
Explore access and support Loading
Download CDC recommendations for 50+
Download
Order Prevnar 20 for your office by registering for Prime
Get started ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CSF=cerebrospinal fluid; HIV=human immunodeficiency virus; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.
*Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.3
†If PCV13 was administered at any age and PPSV23 was administered before age 65 years with the last pneumococcal vaccine being at least 5 years prior, then the patient is eligible for Prevnar 20 as part of a routine vaccination. Based on shared clinical decision-making, a patient is eligible to receive Prevnar 20 if PCV13 (but not PCV15, PCV20, or PCV21) was administered at any age, PPSV23 was administered at or after the age of 65, and the last pneumococcal vaccine was at least 5 years prior.3
‡Adults with chronic medical conditions were previously not recommended to receive PCV13, and there is no current CDC recommendation for those who have received both PCV13 and PPSV23.3
§Also applies to those with an immunocompromising condition (listed below) who have received PCV13 plus 2 doses of PPSV23.3

Underlying medical conditions or other risk factors:

Alcoholism; chronic heart disease (including CHF and cardiomyopathies); chronic liver disease; chronic lung disease (including COPD, emphysema, and asthma); chronic renal failure||; cigarette smoking; cochlear implant; congenital or acquired asplenia||; cerebrospinal fluid leak; diabetes; generalized malignancy||; HIV infection||; Hodgkin disease||; congenital or acquired immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders [excluding chronic granulomatous disease])||; iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)||; leukemia||; lymphoma||; multiple myeloma||; nephrotic syndrome||; solid organ transplant||; sickle cell disease or other hemoglobinopathies||.3
||Immunocompromising conditions.3
References:Prevnar 20 ® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.  Kobayashi M. Summary of Work Group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. Presented at: Advisory Committee on Immunization Practices; October 23, 2024; Atlanta, GA. Accessed October 23, 2024. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pneumococcal-508.pdf  Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 2024. Accessed November 13, 2024. https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-2559 © 2025 Pfizer Inc.
All rights reserved. January 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2559
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20® in individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.INDICATIONS
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine